GlaxoSmithKline said a European Medicines Agency (EMA) panel recommended for approval the company’s three-in-one inhaled lung drug.
Pfizer Inc. and Astellas Pharma Inc. said their drug to treat a type of prostate cancer met the main goal of improving overall survival in a late-stage trial.
AstraZeneca agreed to sell the U.S. rights to a portfolio of anesthetics to South Africa’s Aspen Group.
Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris Treatment for Patients with Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals Inc. announced results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
Teva Pharmaceutical Industries Ltd. is close to a deal to sell its women’s health assets outside the United States to private equity firm CVC Capital Partners, the Fly reported, citing Bloomberg.
A U.S. Food and Drug Administration advisory panel voted 11-0 that the safety and efficacy of GlaxoSmithKline’s Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.
Many of the same things people should do for a healthy heart – such as exercising, eating well and avoiding cigarettes – can also help protect the brain from cognitive decline and dementia, according to the American Heart Association and the American Stroke Association.
Scientists often fail to publicly register plans for clinical trials or to publish the results, and the outcomes they do share may mask instances when new treatments are unsafe or ineffective, a small study suggests.
The hope of new measures for the FDA to advance the regulatory path for drug development is forging ahead incorporating relatively swift pivotal data in seeking accelerated approvals.
Otonomy is cutting jobs and slashing operations in order to stay in business.
BridgeBio Pharma, which was founded in 2015, recently closed on a $135 million series C round that was co-led by Viking Global Investors and KKR. They were joined by Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Janus Funds.
On Sept. 11, 2017, Regeneron Pharmaceuticals and Sanofi announced positive data for its Phase III LIBERTY ASTHMA QUEST trial of Dupixent (dupilumab) in asthma. Investors and analysts do not seem to agree on whether dupilumab is on its way to being one of the biggest blockbuster drugs in the last two years, or if it’s the most overhyped drug on the market.
Amicus Therapeutics terminated a late-stage wound-treatment therapeutic after it failed to meet primary and secondary endpoints in a Phase III trial.
Purohit Navigation, a full-service healthcare communications and advertising agency, hired Brad Sherrill as Vice President of Account Services.
Proposed United States budget cuts could put in jeopardy great progress in reducing global poverty and disease and lead to 5 million more deaths from AIDS alone, the philanthropist Bill Gates warned.
Leaders of the U.S. Senate Finance Committee said they reached an agreement to finance a federal insurance program for millions of lower-income children and pregnant women that was due to expire at the end of September 2017.
Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.
Texas launched aerial attacks on mosquitoes swarming coastal regions of the state and threatening to spread disease and hinder disaster recovery in the aftermath of Hurricane Harvey.
Vertex Pharmaceuticals reportedly terminated a long-acting trial combining a recently acquired therapy with the company’s cystic fibrosis drug Kalydeco.
Sage Therapeutics Inc.’s shares tumbled 23 percent after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial.